Company Profile
PTC Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- PTCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
75.80 USD (-1.33%)
Close
Last updated: July 27, 2026
5.66B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PTCT closed down 1.33% at $75.80. No new same-company headline was identified in the current news window.
Company overview
Business overview
PTC Therapeutics is a biopharmaceutical company focused on rare disease and gene-related therapies. Its story combines commercial products with a pipeline aimed at genetically defined conditions.
Geographic Base and Sector Classification
PTC Therapeutics is headquartered in the United States and listed on NASDAQ. It sits in rare-disease biotechnology.
Business Model Characteristics
The company depends on product sales, regulatory milestones, and pipeline development across multiple orphan areas. Investors watch revenue, label expansion, and program progress.
Position Within the Biotechnology Landscape
PTC occupies a strong rare-disease niche within biotech. It has both commercial grounding and catalyst sensitivity, which makes the stock more durable than a pure development name.
Future catalysts
PTC Therapeutics’s catalysts are sepiapterin, rare-disease commercialization, and any label / pipeline update that extends the growth franchise. The company will be judged on whether its orphan-drug base keeps compounding.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
CAPR · Source: Capricor Therapeutics
- 02
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
KRYS · Source: Krystal Biotech
- 03
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
MNPR · Source: Monopar
- 04
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
ARWR · Source: Arrowhead Pharmaceuticals
- 05
BioCryst to Report Second Quarter 2026 Financial Results on August 5
BCRX · Source: BioCryst Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PTC Therapeutics, Inc. (PTCT)?
PTC Therapeutics, Inc. (PTCT) most recently closed at 75.80 USD, a -1.33% move versus the previous session.
What is the market cap of PTC Therapeutics, Inc. (PTCT)?
PTC Therapeutics, Inc. currently has a market capitalization of 5.66B USD on BioPharmSignal.
What does PTC Therapeutics, Inc. do?
PTC Therapeutics is a biopharmaceutical company focused on rare disease and gene-related therapies. Its story combines commercial products with a pipeline aimed at genetically defined conditions.
On which exchange is PTCT stock listed?
PTC Therapeutics, Inc. (PTCT) is associated with NASDAQ, United States, Biopharma.
What is Therapeutics?
PTC Therapeutics’s catalysts are sepiapterin, rare-disease commercialization, and any label / pipeline update that extends the growth franchise.
Which conditions is PTC Therapeutics, Inc. targeting with Therapeutics?
PTC Therapeutics, Inc. is associated with rare disease, genetic disease based on its company overview and current catalyst commentary.
How does PTC Therapeutics, Inc. describe recent progress with Therapeutics?
PTC Therapeutics’s catalysts are sepiapterin, rare-disease commercialization, and any label / pipeline update that extends the growth franchise.
What future catalysts are investors watching for PTC Therapeutics, Inc.?
PTC Therapeutics’s catalysts are sepiapterin, rare-disease commercialization, and any label / pipeline update that extends the growth franchise. The company will be judged on whether its orphan-drug base keeps compounding.